Patent application number | Description | Published |
20080233638 | PAAD domain-containing polypeptides, encoding nucleic acids, and methods of use - The invention provides isolated nucleic acid molecules encoding PAAD-domain containing polypeptides and functional fragments thereof, including fragments containing PAAD domains, NACHT domains and ARED domains, encoded polypeptides, and antibodies. Also provided are methods of identifying polypeptides and agents that associate with a PAAD-domain containing polypeptide or fragment thereof, or that alter an association of a PAAD domain-containing polypeptides. Further provided are methods of identifying agents that modulate PAAD domain-mediated inhibition of NFκB activity, or modulate an activity of a NACHT domain of a PAAD domain-containing polypeptide. Also provided are methods of modulating NFκB transcriptional activity in a cell, and methods of altering expression of a PAAD domain-containing polypeptide in a cell. | 09-25-2008 |
20080293699 | Inhibitors of thapsigargin-induced cell death - Methods for screening for inhibitors of endoplasmic reticulum (ER) stress are provided. These methods involve the addition of thapsigargin, which induces ER stress, and a test agent to mammalian cells in multi-well plates. Cell survival can be readily monitored by measuring intracellular ATP content using a bioluminescent reagent. Screening a commercially available library of 50,000 compounds led to the identification of 93 hit compounds that were subjected to secondary assays to confirm their ability to rescue cells from thapsigargin-induced cell death. | 11-27-2008 |
20090043099 | Methods and compositions for derepression of IAP-inhibited caspase - The invention provides isolated agents having novel chemical structures and possessing superior activity as derepressors of IAP inhibited caspase. The invention further provides a method of derepressing an IAP-inhibited caspase. The invention further provides assay methods employing labeled compounds of the invention, especially fluorescent labeled compounds. | 02-12-2009 |
20090069324 | CHEMICAL INHIBITORS OF BFL-1 AND RELATED METHODS - Compounds that bind to Bfl-1 as well as conjugates of such compounds are provided. Various embodiments additionally provide methods of using such compounds to identify additional anti-apoptotic Bfl-1 binding compounds. Methods of using such compounds to increase apoptosis in a cell are also provided. | 03-12-2009 |
20090075292 | METHODS FOR IDENTIFYING MODULATORS OF APOPTOSIS - The invention provides a method of identifying an effective compound that modulates the binding of Humanin to Bax or Bid. The invention also provides a method of identifying an effective compound that modulates an activity of Bax or Bid. In addition, the invention provides a method of identifying a Humanin-like compound that binds to Bax or Bid or modulates an activity of Bax or Bid, or inhibits the apoptotic activity of Bax or Bid. The invention further provides an isolated polypeptide containing a mitochondrial-derived form of Humanin (SEQ ID NO:3) or a functional fragment thereof where the fragment contains the methionine at position 16 of SEQ ID NO:3. | 03-19-2009 |
20090118135 | METHODS AND COMPOUNDS FOR REGULATING APOPTOSIS - An assay for determining compounds that inhibit activity of a BCl-2 protein, or affect conversion of Bcl-2 from an antiapoptotic to a proapoptotic form are described. In addition, compounds that modulate the function of anti-apoptotic proteins such as Bcl-2 and related Bcl-2 family members are identified. | 05-07-2009 |
20090123949 | METHODS FOR DETERMINING THE PROGNOSIS FOR CANCER PATIENTS USING TUCAN - The invention provides methods for determining a prognosis for survival for a cancer patient. One method involves (a) measuring a level of a TUCAN in a neoplastic cell-containing sample from the cancer patient, and (b) comparing the level of TUCAN in the sample to a reference level of TUCAN, wherein a low level of TUCAN in the sample correlates with increased survival of the patient. Another method involves (a) measuring a level of TUCAN in a neoplastic cell-containing sample from the cancer patient, and (b) classifying the patient as belonging to either a first or second group of patients, wherein the first group of patients having low levels of TUCAN is classified as having an increased likelihood of survival compared to the second group of patients having high levels of TUCAN. | 05-14-2009 |
20090131646 | Novel bag proteins and nucleic acid molecules encoding them - The present invention provides a family of BAG-1 related proteins from humans (BAG-1L, BAG-1, BAG-2, BAG-3, BAG-4 and BAG-5), the invertebrate | 05-21-2009 |
20090215984 | CONVERSION OF APOPTOTIC PROTEINS - Compounds that modulate the function of anti-apoptotic proteins such as Bcl-2 and Bcl-X | 08-27-2009 |
20090269731 | E3-INDEPENDENT UBIQUITINYLATION ASSAY - Disclosed herein are compositions and methods for assaying ubiquitination independent of ubiquitin ligase (E3) or a target protein. | 10-29-2009 |
20090275040 | DETECTING BCL-B EXPRESSION IN CANCER AND USES THEREOF - Provided herein are compositions and methods of detecting Bcl-B expression in cancer cells to prognose, monitor, or select therapies for cancers such as breast cancer, prostate cancer, lung cancer, or gastric cancer. | 11-05-2009 |
20090305904 | APOPTOSIS MODULATOR BCL-B AND METHODS FOR MAKING AND USING SAME - A novel human member of the Bcl-2 family Bcl-B has been identified, which is closest in amino-acid sequence homology to the Boo (Diva) protein. The Bcl-B protein is widely expressed in adult human tissues. The Bcl-B protein modulates apoptosis. Bcl-B also binds Bcl-2. BCl-XL, and Bax but not Bak. Bcl-B displays a unique pattern of selectivity for binding and regulating the function of other members of the Bcl-2 family. | 12-10-2009 |
20100028892 | YEAST BASED EXPRESSION OF PROTEASES AND METHODS OF USE - This disclosure generally relates to components and methods of using a high throughput screening (HTS) systems for intracellular proteases, using Caspases as a prototype. Genetic systems are disclosed for monitoring exogenous caspase activation pathways in the yeast, | 02-04-2010 |
20100093623 | COMPOSITIONS AND METHODS FOR MODULATING NOD-LIKE RECEPTOR ACTIVITY AND USES THEREOF - Disclosed herein are compositions and methods relating to a peptide that inhibits Nod-like Receptors. Further provided are compositions and methods for treating or preventing inflammation, including diseases associated with inflammation such as inflammatory bowel disease, Crohn's disease, ulcerative colitis, arthritis, psoriasis, Alzheimer's disease, cardiovascular disease, diabetes, and sepsis. | 04-15-2010 |
20100189720 | NOVEL CARD PROTEINS INVOLVED IN CELL DEATH REGULATION - The present invention provides NB-ARC and CARD-containing proteins (NACs), nucleic acid molecules encoding NACs and antibodies specific for at least one NAC. The invention further provides chimeric NAC proteins. The invention also provides screening assays for identifying an agent that can effectively alter the association of a NAC with a NAC-associated protein. The invention further provides methods of modulating apoptosis in a cell by introducing into the cell a nucleic acid molecule encoding a NAC or an antisense nucleotide sequence. The invention also provides a method of using a reagent that can specifically bind to a NAC to diagnose a pathology that is characterized by an increased or decreased level of apoptosis in a cell. | 07-29-2010 |
20100190195 | Use of Hepatitis B X-Interacting Protein (HBXIP) in Modulation of Apoptosis - Novel methods of regulating cellular apoptosis by affecting the interaction of hepatitis B X-interacting protein (HBXIP) with Survivin are described. More specifically, these novel methods of enhancing apoptosis of neoplastic cells comprises inhibiting interaction of hepatitis B X-interacting protein (HBXIP) with Survivin using siRNA or antisense compounds. | 07-29-2010 |
20100261788 | Inhibition of Bid-Induced Cell-Death Using Small Organic Molecules - Various phenylamine derivatives are described as well as the use of compounds to inhibit BID protein for controlling apoptotic cascade. | 10-14-2010 |
20100275284 | INHIBITOR OF APOPTOSIS PROTEINS AND NUCLEIC ACIDS AND METHODS FOR MAKING AND USING THEM - The invention provides polypeptides comprising inhibitor of apoptosis protein (IAP) family members, such as BmIAP initially derived from | 10-28-2010 |
20100279300 | METHODS FOR DETERMINING THE PROGNOSIS FOR PATIENTS WITH A PROSTATE NEOPLASTIC CONDITION - The invention provide a method of identifying a biomarker that is diagnostic for survival of a patient with a prostate neoplastic condition. The method consists of (a) measuring the level of IAPs in a neoplastic prostate cell-containing sample from patients with a prostate neoplastic condition, and (b) identifying a correlation between the level of IAPs in a sample from a patient with the survival of that patient, where the correlation of an IAP with survival in patients indicates the IAP is a biomarker diagnostic of survival of a patient with a prostate neoplastic condition. Also provided is a method of determining a prognosis for survival for a patient with a prostate neoplastic condition. The method consists of (a) measuring the level of XIAP in a neoplastic prostate cell-containing sample from the patient, and (b) comparing the level of XIAP in the sample to a reference level of XIAP, where an increased level of XIAP in the sample correlates with increased survival of the patient. The invention further provides a method of determining a prognosis for survival for a patient with a prostate neoplastic condition. The method consists of (a) measuring the level of two or more IAPs selected from the group consisting of XIAP, cIAP1, and cIAP2 in a neoplastic prostate cell-containing sample from a patient, and (b)comparing the level of the two or more IAPs in the sample to a reference level of the IAPs, where an increased level of XIAP and decreased level of cIAP1 or cIAP2 in the sample correlates with increased survival of the patient. | 11-04-2010 |
20100324267 | NOVEL TRAF FAMILY PROTEINS - In accordance with the present invention, there are provided novel TRAF-Protein-Binding-Domain polypeptides (TPBDs). The invention also provides nucleic acid molecules encoding TPBDs, vectors containing these nucleic acid molecules and host cells containing the vectors. The invention also provides antibodies that can specifically bind to invention TPBDs. Such TPBDs and/or anti-TPBD antibodies are useful for discovery of drugs that suppress autoimmunity, inflammation, allergy, allograph rejection, sepsis, and other diseases. | 12-23-2010 |
20110008319 | CARD DOMAIN CONTAINING POLYPEPTIDES, ENCODING NUCLEIC ACIDS, AND METHODS OF USE - The invention provides caspase recruitment domain (CARD)-containing polypeptides, CARD, NB-ARC, ANGIO-R, LRR and SAM domains therefrom, as well as encoding nucleic acid molecules and specific antibodies. The invention also provides related screening, diagnostic and therapeutic methods. | 01-13-2011 |
20110027260 | BCL-G POLYPEPTIDES, ENCODING NUCLEIC ACIDS AND METHODS OF USE - The invention provides Bcl-G polypeptides and encoding nucleic acids. Bcl-G polypeptides include Bcl-G | 02-03-2011 |
20110028690 | NOVEL BAG PROTEINS AND NUCLEIC ACID MOLECULES ENCODING THEM - The present invention provides a family of BAG-1 related proteins from humans (BAG-1L, BAG-1, BAG-2, BAG-3, BAG-4 and BAG-5), the invertebrate | 02-03-2011 |
20110059465 | SCREENING ASSAYS FOR AGENTS THAT ALTER INHIBITOR OF APOPTOSIS (IAP) PROTEIN REGULATION OF CASPASE ACTIVITY - The present invention relates to an action between an inhibitor of apoptosis (IAP) protein and members of the caspase family of cell death proteases, for example, an interaction of the X chromosome linked IAP (XIAP) and caspase-3, caspase-7 or caspase-9, wherein the IAP regulates the activity of the caspases. The invention provides screening assays for identifying agents that alter the specific association of an IAP such as XIAP, c-IAP-1 or c-IAP-2 and a caspase such as caspase-3 or caspase-7. The invention also provides screening assays for identifying agents that alter the specific association of an IAP such as XIAP, c-IAP-1 or c-IAP-2 and a pro-caspase such as pro-caspase-9. In addition, the invention also provides methods for identifying agents that modulate the activity of a caspase in the presence of an IAP and that regulate the activation of a pro-caspase by an IAP. The invention further provides methods of reducing the severity of a pathologic condition in an individual by administering to the individual an agent that alters the caspase inhibitory activity of an IAP. In addition, the invention provides methods of modulating the ability of a population of cells to survive ex vivo by contacting the cells with an agent that alters the caspase inhibitory activity of an IAP in the cells. | 03-10-2011 |
20110288002 | NOVEL BAG PROTEINS AND NUCLEIC ACID MOLECULES ENCODING THEM - The present invention provides a family of BAG-1 related proteins from humans (BAG-1L, BAG-1, BAG-2, BAG-3, BAG-4 and BAG-5), the invertebrate | 11-24-2011 |
20110318362 | NOVEL CARD PROTEINS INVOLVED IN CELL DEATH REGULATION - The present invention provides NB-ARC and CARD-containing proteins (NACs), nucleic acid molecules encoding NACs and antibodies specific for at least one NAC. The invention further provides chimeric NAC proteins. The invention also provides screening assays for identifying an agent that can effectively alter the association of a NAC with a NAC-associated protein. The invention further provides methods of modulating apoptosis in a cell by introducing into the cell a nucleic acid molecule encoding a NAC or an antisense nucleotide sequence. The invention also provides a method of using a reagent that can specifically bind to a NAC to diagnose a pathology that is characterized by an increased or decreased level of apoptosis in a cell. | 12-29-2011 |
20120046195 | DETECTING BCL-B EXPRESSION IN CANCER AND USES THEREOF - Provided herein are compositions and methods of detecting Bcl-B expression in cancer cells to prognose, monitor, or select therapies for cancers such as breast cancer, prostate cancer, lung cancer, or gastric cancer. | 02-23-2012 |
20120094922 | SCREENING ASSAYS FOR AGENTS THAT ALTER INHIBITOR OF APOPTOSIS (IAP) PROTEIN REGULATION OF CASPASE ACTIVITY - The present invention relates to an action between an inhibitor of apoptosis (IAP) protein and members of the caspase family of cell death proteases, for example, an interaction of the X chromosome linked IAP (XIAP) and caspase-3, caspase-7 or caspase-9, wherein the IAP regulates the activity of the caspases. The invention provides screening assays for identifying agents that alter the specific association of an IAP such as XIAP, c-IAP-1 or c-IAP-2 and a caspase such as caspase-3 or caspase-7 or a pro-caspase such as pro-caspase-9, or that modulate the activity of a caspase in the presence of an IAP and that regulate the activation of a pro-caspase by an IAP. The invention further provides methods of reducing the severity of a pathologic condition in an individual by administering to the individual an agent that alters the caspase inhibitory activity of an IAP. | 04-19-2012 |
20120245147 | INHIBITORS OF THAPSIGARGIN-INDUCED CELL DEATH - Methods for screening for inhibitors of endoplasmic reticulum (ER) stress are provided. These methods involve the addition of thapsigargin, which induces ER stress, and a test agent to mammalian cells in multi-well plates. Cell survival can be readily monitored by measuring intracellular ATP content using a bioluminescent reagent. Screening a commercially available library of 50,000 compounds led to the identification of 93 hit compounds that were subjected to secondary assays to confirm their ability to rescue cells from thapsigargin-induced cell death. | 09-27-2012 |
20130224182 | BCL-G POLYPEPTIDES, ENCODING NUCLEIC ACIDS AND METHODS OF USE - The invention provides Bcl-G polypeptides and encoding nucleic acids. Bcl-G polypeptides include Bcl-G | 08-29-2013 |